HOME > Corporate Information > Corporate History
Dainippon Sumitomo Pharma
| 2005 | October 1, Dainippon Sumitomo Pharma created. |
|---|---|
| 2006 | Co-promotion of SEIBULE® (ameliorating agent for postprandial hyperglycemia due to diabetes) started. AmBisome® (therapeutic agent for systemic fungal infection) launched. AMLODIN® OD tablet (therapeutic agent for hypertension and angina pectoris) launched. |
| 2007 | REPLAGAL® (therapeutic agent for Anderson-Fabry disease) launched. The laboratory products business was transferred to DS Pharma Biomedical Co., Ltd. The mid-term business plan (for the period from fiscal 2007 to fiscal 2009) started. |
| 2008 | LONASEN® (atypical antipsychotic) launched. AVAPRO® (therapeutic agent for hypertension) launched. |
| 2009 | TRERIEF® (Parkinson's disease drug) launched. A holding company(Dainippon Sumitomo Pharma America Holdings, Inc.) established in the United States. Acquired Sepracor Inc. (Current Sunovion Pharmaceuticals Inc.), Sepracor (Current Sunovion Pharmaceuticals Inc.) became a wholly owned subsidiary of the U.S. holdings company. |
| 2010 | MIRIPLA® (therapeutic agent for hepatocellular carcinoma) launched. The second mid-term business plan (for the period from fisical 2010 to fisical 2014) started. Sepracor Inc. (Current Sunovion Pharmaceuticals Inc.) and Dainippon Sumitomo Pharma America, Inc. merged. METGLUCO® (biguanide oral hypoglycemic) launched. Growth hormone business transferred. The Animal Health Products business split off and DS Pharma Animal Health Co., Ltd. established. The Food & Speciality Products business integrated into its subsidiary Gokyo Trading Co., Ltd. and corporate name changed to DSP Gokyo Food & Chemical Co., Ltd. Sepracor Inc. changed its company name to Sunovion Pharmaceuticals Inc. |
| 2011 | LATUDA® (atypical antipsychotic) launched in the United States by Sunovion Pharmaceuticals Inc. Radarcirc® Business transferred. SUREPOST® (rapid-acting insulin secretagogue) launched. |
| 2012 | Acquired Boston Biomedical, Inc., Boston Biomedical,
Inc. became a wholly-owned subsidiary. Co-promotion of Paxil®CR Tablets (Selective serotonin reuptake inhibitor) started. AIMIX® Combination Tablets LD/HD (anti-hypertension drug) launched. |
| 2013 | A Subsidiary (Sunovion Pharmaceuticals Asia Pacific Pte Ltd.) established in Singapore. The third mid-term business plan (for the period from fisical 2013 to fisical 2017) started. Dainippon Sumitomo Pharma Europe Ltd. changed its company name to Sunovion Pharmaceuticals Europe Ltd. |
Dainippon Pharmaceutical
The history of Dainippon Pharmaceutical is introduced.
Sumitomo Pharmaceuticals
The history of Sumitomo Pharmaceuticals is introduced.
